Extended Zerlasiran Data Show Sustained Lp(a) Reduction
The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.
Medscape Medical News
source https://www.medscape.com/viewarticle/extended-zerlasiran-data-show-sustained-lp-reduction-2024a10006zm?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/extended-zerlasiran-data-show-sustained-lp-reduction-2024a10006zm?src=rss
Comments
Post a Comment